Stox
80
Metropolis Healthcare Limited
NSE: METROPOLIS · Healthcare
₹568.75-0.39%06 Nov 2026
Ask the data
Instant answers about Metropolis Healthcare Limited — computed from its filings, no language modelMarket cap₹11,799 cr
Current price₹568.75
High / Low₹602 / ₹422
P/E52.6
P/B7.19
Book value₹79.1
ROE13.7%
ROCE20.1%
Debt / equity0.01
Dividend yield0.18%
EPS (TTM)₹10.81
Face value₹2
Price & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | 856 | 998 | 1,228 | 1,148 | 1,208 | 1,331 | 1,646 |
| EBITDA | 233 | 286 | 343 | 288 | 283 | 303 | 401 |
| Operating margin | 27.2% | 28.7% | 27.9% | 25.1% | 23.4% | 22.8% | 24.4% |
| Interest | 8 | 8 | 20 | 27 | 23 | 19 | 25 |
| Depreciation | 39 | 46 | 63 | 89 | 94 | 109 | 134 |
| Profit before tax | 169 | 244 | 293 | 188 | 175 | 191 | 259 |
| Tax | 41 | 61 | 79 | 44 | 46 | 45 | 68 |
| Net profit | 127 | 183 | 214 | 143 | 128 | 145 | 190 |
| EPS ₹ | 25.36 | 35.97 | 41.87 | 27.91 | 24.95 | 28.29 | 9.19 |
| Operating cash flow | — | — | 253 | 247 | 264 | 263 | 351 |
| Capex | — | — | 31 | 53 | 64 | 69 | 36 |
| Dividend paid | — | — | 41 | 41 | 20 | 18 | 21 |
| Total assets | — | — | — | 1,502 | 1,555 | 1,867 | 2,138 |
| Equity | — | — | — | 988 | 1,096 | 1,331 | 1,513 |
Quarterly performance
last 30 quarters · ₹ crore| JUN '19 | SEP '19 | DEC '19 | MAR '20 | JUN '20 | SEP '20 | DEC '20 | MAR '21 | JUN '21 | SEP '21 | DEC '21 | MAR '22 | JUN '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | MAR '25 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 203 | 223 | 223 | 207 | 143 | 288 | 275 | 292 | 327 | 303 | 293 | 306 | 280 | 300 | 285 | 283 | 277 | 308 | 291 | 331 | 313 | 350 | 323 | 345 | 386 | 429 | 406 | 425 | 450 | 497 |
| Operating profit | 55 | 63 | 64 | 51 | 12 | 91 | 87 | 96 | 102 | 90 | 75 | 75 | 68 | 79 | 70 | 70 | 63 | 75 | 65 | 80 | 79 | 90 | 72 | 62 | 90 | 108 | 95 | 108 | 111 | 134 |
| Operating margin | 27.1% | 28.0% | 28.5% | 24.8% | 8.5% | 31.5% | 31.5% | 33.0% | 31.3% | 29.8% | 25.7% | 24.5% | 24.5% | 26.3% | 24.7% | 24.9% | 22.7% | 24.2% | 22.3% | 24.2% | 25.1% | 25.7% | 22.3% | 18.0% | 23.3% | 25.2% | 23.4% | 25.4% | 24.7% | 27.0% |
| Other income | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 2 | 4 | 6 | 3 | 6 | 3 | 4 | 7 | 1 | 3 | 1 | 2 | 3 | 2 | 3 | 3 | 7 | 8 | 1 | 9 | 8 | 5 | 8 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 3 | 5 | 6 | 8 | 7 | 6 | 6 | 6 | 6 | 5 | 6 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 8 | 6 | 7 |
| Depreciation | 8 | 9 | 11 | 11 | 10 | 11 | 11 | 14 | 13 | 15 | 17 | 18 | 21 | 22 | 23 | 23 | 21 | 22 | 25 | 26 | 26 | 27 | 28 | 29 | 31 | 32 | 32 | 39 | 32 | 33 |
| Profit before tax | 40 | 53 | 53 | 23 | 4 | 81 | 78 | 82 | 103 | 78 | 56 | 56 | 43 | 55 | 48 | 42 | 39 | 48 | 37 | 51 | 51 | 61 | 42 | 36 | 61 | 71 | 57 | 70 | 78 | 102 |
| Tax | 12 | 10 | 11 | 8 | 1 | 21 | 19 | 20 | 28 | 19 | 15 | 16 | 9 | 14 | 12 | 8 | 10 | 12 | 10 | 14 | 13 | 15 | 11 | 7 | 16 | 18 | 15 | 19 | 21 | 27 |
| Net profit | 27 | 43 | 42 | 15 | 3 | 60 | 59 | 61 | 75 | 58 | 41 | 40 | 33 | 40 | 36 | 33 | 29 | 35 | 27 | 36 | 38 | 47 | 31 | 29 | 45 | 53 | 41 | 51 | 57 | 75 |
| EPS ₹ | 5.34 | 8.57 | 8.38 | 3.09 | 0.57 | 11.88 | 11.50 | 12.05 | 14.65 | 11.39 | 8.02 | 7.81 | 6.53 | 7.88 | 6.99 | 6.51 | 5.62 | 6.92 | 5.30 | 7.11 | 7.41 | 9.08 | 6.11 | 5.69 | 8.70 | 10.17 | 7.99 | 2.46 | 2.73 | 3.64 |
| Revenue YoY | — | — | — | — | -29.6% | 29.1% | 23.3% | 41.0% | 128.3% | 4.9% | 6.6% | 4.9% | -14.4% | -0.8% | -2.6% | -7.6% | -1.0% | 2.7% | 2.0% | 17.1% | 13.1% | 13.4% | 10.9% | 4.3% | 23.2% | 22.7% | 25.8% | 23.0% | 16.6% | 15.8% |
| Profit YoY | — | — | — | — | -89.2% | 40.3% | 39.2% | 296.1% | 2482.4% | -3.3% | -29.9% | -34.8% | -55.4% | -30.8% | -12.8% | -16.6% | -13.8% | -12.1% | -24.1% | 9.1% | 31.8% | 31.2% | 15.5% | -20.0% | 18.7% | 13.2% | 32.0% | 74.7% | 25.8% | 43.0% |
Returns & margins
trailing-twelve-month, per quarter| MAR '20 | JUN '20 | SEP '20 | DEC '20 | MAR '21 | JUN '21 | SEP '21 | DEC '21 | MAR '22 | JUN '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | MAR '25 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | 16.2% | 15.6% | 14.5% | 14.0% | 12.7% | 11.9% | 11.7% | 12.5% | 12.5% | 12.9% | 10.9% | 11.4% | 11.0% | 11.7% | 12.6% | 13.3% | 13.7% |
| ROCE | — | — | — | — | — | — | — | — | — | — | 21.5% | 20.9% | 20.1% | 19.6% | 18.4% | 17.3% | 18.0% | 19.0% | 18.6% | 19.0% | 15.6% | 16.4% | 15.9% | 17.0% | 18.5% | 19.7% | 20.1% |
| Net margin | 14.9% | 13.0% | 14.0% | 15.0% | 18.3% | 21.6% | 21.2% | 19.4% | 17.4% | 14.6% | 13.1% | 12.8% | 12.4% | 12.1% | 11.6% | 10.8% | 10.6% | 11.0% | 11.5% | 11.6% | 10.9% | 10.8% | 10.7% | 10.7% | 11.5% | 11.8% | 12.6% |
| EBITDA margin | 27.2% | 23.8% | 25.3% | 26.4% | 28.7% | 31.8% | 31.4% | 30.0% | 27.9% | 26.1% | 25.2% | 25.0% | 25.1% | 24.7% | 24.1% | 23.5% | 23.4% | 24.0% | 24.4% | 24.4% | 22.8% | 22.4% | 22.4% | 22.7% | 24.4% | 24.7% | 25.2% |
| Debt / equity | — | — | — | — | — | — | — | — | — | — | 0.14 | 0.14 | 0.08 | 0.08 | 0.04 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Interest coverage | 21.27 | 16.73 | 20.91 | 26.35 | 32.40 | 30.75 | 26.99 | 20.42 | 15.85 | 11.78 | 9.23 | 8.57 | 8.00 | 8.28 | 8.40 | 8.18 | 8.75 | 9.80 | 10.84 | 11.51 | 11.28 | 11.51 | 11.53 | 11.63 | 11.56 | 11.80 | 12.45 |
| Asset turnover | — | — | — | — | — | — | — | — | — | — | 0.78 | 0.78 | 0.76 | 0.76 | 0.76 | 0.77 | 0.78 | 0.80 | 0.79 | 0.81 | 0.71 | 0.75 | 0.74 | 0.79 | 0.77 | 0.80 | 0.76 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '22 | MAR '23 | SEP '23 | MAR '24 | SEP '24 | MAR '25 | SEP '25 | MAR '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Share capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 41 | 41 |
| Other equity / reserves | 946 | 978 | 1,036 | 1,086 | 1,174 | 1,321 | 1,422 | 1,472 | 1,600 |
| Total equity | 957 | 988 | 1,046 | 1,096 | 1,184 | 1,331 | 1,432 | 1,513 | 1,642 |
| Borrowings | 138 | 79 | 44 | 0 | 0 | 14 | 21 | 19 | 17 |
| Current liabilities | 289 | 265 | 250 | 246 | 238 | 294 | 302 | 334 | 371 |
| Non-current liabilities | 259 | 246 | 209 | 210 | 206 | 238 | 247 | 279 | 316 |
| Total assets | 1,507 | 1,502 | 1,509 | 1,555 | 1,631 | 1,867 | 1,993 | 2,138 | 2,341 |
| Property, plant & equipment | 297 | 137 | 145 | 156 | 164 | 190 | 203 | 215 | 222 |
| Capital work-in-progress | 0 | 0 | 0 | 0 | — | 0 | — | 0 | — |
| Investments | 29 | 15 | 38 | 55 | 132 | 71 | 21 | 337 | 271 |
| Inventories | 38 | 45 | 44 | 39 | 37 | 48 | 43 | 45 | 51 |
| Receivables | 124 | 122 | 123 | 126 | 134 | 148 | 176 | 170 | 184 |
| Cash & equivalents | 70 | 69 | 51 | 63 | 44 | 39 | 50 | 55 | 69 |
Cash flow
annual · ₹ crore · line = free cash flow| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Cash from operations | 253 | 247 | 264 | 263 | 351 |
| Cash from investing | -735 | 47 | -89 | -201 | -223 |
| Cash from financing | 163 | -292 | -181 | -87 | -115 |
| Capex | 31 | 53 | 64 | 69 | 36 |
| Free cash flow | 223 | 194 | 200 | 194 | 315 |
| Dividends paid | 41 | 41 | 20 | 18 | 21 |
Where the assets sit
Sep '26 · ₹ croreFixed assets (PPE)₹222 cr9%
Investments₹271 cr12%
Inventories₹51 cr2%
Receivables₹184 cr8%
Cash & equivalents₹69 cr3%
Other assets₹1,544 cr66%
Peer comparison
largest in Healthcare · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,270 | 1,860.00 | 40.7 | 5.00 | 12.3% |
| Divi's Laboratories Ltd. | 2,73,493 | 10,320.50 | 93.5 | 16.32 | 17.5% |
| Torrent Pharmaceuticals Ltd. | 1,80,671 | 4,750.00 | 85.1 | 9.83 | 11.6% |
| Laurus Labs Ltd. | 1,26,430 | 2,340.00 | 94.4 | 20.86 | 22.1% |
| Apollo Hospitals Enterprise Ltd. | 1,21,453 | 8,446.00 | 54.2 | 11.45 | 21.1% |
| Zydus Lifesciences Ltd. | 1,19,550 | 1,197.90 | 28.6 | 4.30 | 15.0% |
| Dr. Reddy's Laboratories Ltd. | 1,14,646 | 1,373.00 | 40.9 | 2.95 | 7.2% |
| Cipla Ltd. | 1,13,988 | 1,411.00 | 39.3 | 3.22 | 8.2% |
| Mankind Pharma Ltd. | 1,04,902 | 2,540.00 | 46.7 | 5.97 | 12.8% |
| Aurobindo Pharma Ltd. | 1,03,572 | 1,800.00 | 26.0 | 2.63 | 10.1% |
| Metropolis Healthcare Limited | 11,799 | 568.75 | 52.6 | 7.19 | 13.7% |
StoxGud checklist: Bullish setup · 8/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
1 month+5.0%
6 months+12.5%
1 year+17.0%
3Y CAGR+13.1%
5Y CAGR-6.2%
10Y CAGR—
50-day avg₹562.73
200-day avg₹523.55
RSI (14)66
FAQs
What is the share price of Metropolis Healthcare Limited?
Metropolis Healthcare Limited (METROPOLIS) closed at ₹568.75 on NSE on 06 Nov 2026.
What is the market cap of Metropolis Healthcare Limited?
₹11,799 crore at the latest close.
What is the P/E ratio of Metropolis Healthcare Limited?
52.6, on trailing-twelve-month earnings from its filings.
How fast is Metropolis Healthcare Limited growing?
Metropolis Healthcare Limited: revenue has compounded at 12.8% a year over three years; net profit at 10.0% a year. Latest-quarter revenue is up 15.8% year on year, profit up 43.0%.
How profitable is Metropolis Healthcare Limited?
On a trailing-twelve-month basis return on equity is 13.7%, return on capital employed 20.1%, operating margin 25.2%, net margin 12.6%.
How much debt does Metropolis Healthcare Limited have?
Metropolis Healthcare Limited is debt-free: debt to equity is 0.01 with borrowings of ₹17 cr against cash of ₹69 cr (balance sheet of 2026-09-30). Operating profit covers interest 12.4 times.
Financials parsed from Metropolis Healthcare Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from JUN '19, annual from FY20, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.
Metropolis Healthcare Limited · advanced chart